

Validation of a guidelines-based digital tool to assess the need for germline cancer genetic testing

Callan D. Russell^{1,2}, Ashley V. Daley¹, Durand R. Van Arnen¹, Andi V Hila¹, Kiley J.

Johnson¹, Jill N. Davies¹, Hanah S. Cytron¹, Kaylene J. Ready³, Cary M. Armstrong¹, Mark

E. Sylvester¹, Colleen A. Caleshu¹

¹Genome Medical, South San Francisco, CA

²Northside Hospital, Atlanta, GA

³Baylor Scott and White, Dallas, TX

Address for Correspondence:

Colleen Caleshu

Address: 611 Gateway Blvd Suite 120, South San Francisco, CA 94080

Ph: (877) 688-0992

Email: colleen@genomemedical.com

Prior presentation of this work: American Society of Clinical Oncology Annual Meeting

2023, National Society of Genetic Counselors Annual Conference 2021, 2023

Running head: Validation of hereditary cancer risk assessment digital tool

This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

ABSTRACT

Purpose: Efficient and scalable solutions are needed to identify patients who qualify for germline cancer genetic testing. We evaluated the clinical validity of a brief, patient-administered hereditary cancer risk assessment digital tool programmed to assess if patients meet criteria for germline genetic testing, based on personal and family history, and in line with national guidelines.

Methods: We applied the tool to cases seen in a nationwide telehealth genetic counseling practice. Validity of the tool was evaluated by comparing the tool's assessment to that of the genetic counselor who saw the patient. Patients' histories were extracted from genetic counselor-collected pedigrees and input into the tool by the research team to model how a patient would complete the tool. We also validated the tool's assessment of which specific aspects of the personal and family history met criteria for genetic testing.

Results: Of the 152 cases (80% ((121/152)) female, mean age 52.3), 56% (85/152) had a personal history of cancer and 66% (99/152) met genetic testing criteria. The tool and genetic counselor agreed in 96% (146/152) of cases. Most disagreements (4/6; 67%) occurred because the GC's assessment relied on details the tool was not programmed to collect since patients typically don't have access to the relevant information (pathology details, risk models). We also found complete agreement between the tool and research team on which specific aspects of the patient's history met criteria for genetic testing.

Conclusion: We observed a high level of agreement with genetic counselor assessments, affirming the tool's clinical validity in identifying individuals for hereditary cancer

predisposition testing and its potential for increasing access to hereditary cancer risk assessment.

INTRODUCTION

At least 5-10% of cancer is hereditary, arising from a germline pathogenic variant in a cancer predisposition gene¹. 8% of individuals in the general population carry such pathogenic variants, yet the vast majority of these individuals do not know they possess this risk.²⁻⁵ Identification of individuals with a hereditary risk of cancer allows for personalized care such as more frequent and earlier cancer screening and risk-reducing surgeries. These measures have been shown to lead to earlier cancer diagnoses, improved prognosis, and/or prevention of cancer.⁶⁻⁸ In addition, among patients with cancer, identification of individuals with certain germline pathogenic variants is necessary for personalized cancer treatment such as PARP inhibitors for those with *BRCA1/2* mutations and immune checkpoint therapies for those with Lynch syndrome.^{9, 10} Given these clinical benefits, multiple professional guidelines recommend that oncologists, obstetricians-gynecologists and primary care doctors perform hereditary cancer risk assessment.^{1, 6, 11-13,}

However, there is ample evidence that in both non-specialty and oncology settings, hereditary cancer risk assessment is not performed as recommended by guidelines.^{2, 4, 14-17} Fewer than 20% of women with a history of breast or ovarian cancer who meet National Comprehensive Cancer Network (NCCN) criteria for germline cancer genetic testing have had such testing.² Most individuals who haven't had testing report never discussing testing with a healthcare provider.² In a 2022 study of over 279,000 women receiving

primary care at the Cleveland Clinic, only 22% of high-risk women had been referred for genetic testing.⁴ Additionally, that study found disparities in referrals based on race with Black individuals significantly less likely to be referred than White individuals. A 2023 study of over 1.3 million cancer patients found that while rates of germline genetic testing after a cancer diagnosis have increased over time, such testing remains heavily underutilized after a cancer diagnosis.¹⁶

Investigations into the reasons that providers do not perform guideline-recommended hereditary cancer risk assessments have revealed that providers perceive such assessments as valuable and important, but they face many barriers to performing them for their patients.^{18–21} Non-genetics providers feel they lack sufficient genetics expertise, do not feel confident answering patient questions related to genetic risk and genetic testing, and have difficulty staying up to date with advances in genetic testing^{18–21}. In addition, providers report they do not have time to adequately assess and counsel patients about hereditary cancer risk.^{18, 21} This is understandable, given it can take up to 30 minutes to collect the extensive family history that is often needed to determine if a patient meets guideline-based criteria.²² Furthermore, such criteria are complex and frequently change, making it difficult for providers to apply them. New approaches to hereditary cancer risk assessment are needed that address these barriers. Several paper-based screening tools have been developed; these are often brief forms completed by patients and scored by clinic staff. While they increase the identification of patients at high risk, they only cover a small subset of testing criteria and thus miss many patients who qualify for genetic testing.^{23–26}

Digital tools have the potential to cover far more testing criteria and to assess patients in an automated fashion that does not depend on clinic staff. A variety of such solutions have arisen in recent years.^{27–31} This includes automated algorithms that leverage family history information already captured in the EHR³¹ as well as patient-facing digital tools that perform hereditary cancer risk assessment based on patient-entered personal and family history.^{27, 28, 30} Studies have found that such digital tools effectively identify at-risk patients who would have been overlooked.^{25, 27, 30, 32–35} Importantly, patients report high levels of satisfaction with digital tools in genomics care.^{20, 27, 33, 36–38} Thus, these digital tools show promise for helping increase access to guideline-recommended hereditary cancer risk assessment. However, appropriate validation of such tools must be performed to ensure the accuracy of their assessments.²⁰ Of those that do report validation, there are mixed results on the sensitivity and specificity of tools. One such study showed 100% sensitivity and 99.5% specificity, however, the low-risk cases were fabricated and the validation only covered assessment for hereditary breast-ovarian cancer and Lynch syndrome²⁸. Validation of another digital risk assessment tool found it failed to identify half of the individuals that genetics clinicians assessed to be at risk for a hereditary cancer predisposition³⁰.

We developed RISE Risk Assessment Module: Hereditary Cancer to help providers perform hereditary cancer risk assessment without a significant time or process burden for them or their clinic staff (Figure 1). This is a brief, patient-administered web-based tool designed to assess whether germline cancer genetic testing may be indicated, consistent with national guidelines. The tool was created by a team of GCs with expertise in oncology, product managers, user experience designers, and software engineers. Patients

answer questions about their personal and family history and the algorithm underlying the tool assesses whether that history indicates genetic testing is appropriate. To increase usability and efficiency, the history questions are programmed with skip logic so patients only see questions relevant to them. Unlike many existing hereditary cancer risk assessment tools, this tool was programmed to detect hereditary risk for a wide range of cancers, hereditary cancer syndromes, and tumors (Table 1). The algorithm is updated as guideline updates are released. The patient is immediately informed of the assessment result (Figure 1) and a separate PDF documenting the relevant history and assessment result is available to the provider in the platform. The platform is HIPAA-compliant and SOC2-certified.

We sought to validate this hereditary cancer risk assessment tool against assessments made by genetic counselors (GCs) specialized in oncology, which is the current gold standard for hereditary cancer risk assessment.

METHODS

To assess the clinical validity of the tool, the tool's assessment of the patient meeting criteria for genetic testing was compared to the assessment made by the board-certified cancer GC who previously saw the patient for clinical care. The tool's assessment was performed retrospectively and as part of this study only (not part of the patient's clinical care).

Patients

Cases were drawn from patients seen for pre-test genetic counseling for hereditary cancer risk in a nationwide telehealth genetic counseling practice between July 23, 2020,

and October 23, 2020. We used purposive sampling to select cases that met criteria for genetic testing (as assessed by the GC who saw the patient for clinical care) to ensure that the sample covered the criteria most frequently invoked in clinical practice and for variance in cancer types. Cases that did not meet criteria for genetic testing (as assessed by the GC who saw the patient for clinical care) were consecutively selected.

Data collection

Patient demographics, personal history of polyps or cancer, family history of cancer, and the GC's assessment of whether the patient met criteria were extracted via retrospective review of the electronic medical record. The tool's assessment was determined by the research team entering the patient's personal and family history into the tool.

Validation

Validity was operationalized as how often the tool's assessment of whether the patient met criteria for genetic testing agreed with the assessment made by the GC who saw the patient clinically. When the tool's assessment and the assessment made by the GC disagreed, a senior cancer GC (AD) reviewed the case to determine the origin of the disagreement.

We further assessed the performance of the tool in a subset of cases by determining the level of agreement between the tool and the research team on which aspects of a patient's history met criteria.

The WIRB-Copernicus Group Institutional Review Board deemed the study exempt and approved a waiver of authorization for use and disclosure of protected health information (PHI) because the study analyzed deidentified secondary data.

RESULTS

The dataset consisted of 152 patients seen for pre-test cancer genetic counseling with two-thirds meeting criteria for genetic testing (per GC assessment) and half having a personal history of cancer, with a variety of cancer types represented including breast, colorectal, uterine, prostate, ovarian, pancreatic, renal, melanoma, and skin (Table 2).

In 96% (146/152) of cases, the tool's assessment of whether the patient met criteria for genetic testing agreed with the GC's assessment (Figure 2). Among patients who met criteria (by GC assessment), there was 95% (94/99) agreement between the tool and GC. Among patients who did not meet criteria (by GC assessment), there was 98% (46/47) agreement between tool and GC.

For the cases (3.9% (6/152)) where there was disagreement between the tool and GC, we examined why the assessments differed. Most differences in assessment (67% (4/6)) occurred because the GC assessment depended on a specific aspect of history that the tool did not ask about. This included microsatellite instability/immunohistochemistry (MSI/IHC) results (50% (3/6)) and risk of having a germline pathogenic variant based on the PRediction Model for gene Mutations (PREMM5; 16.7% (1/6))³⁹. Disagreement occurred in one case because the GC applied their clinical expertise in interpreting the patient's polyp history as meeting criteria based on likely polyp type, while the tool assessed the patient as not meeting criteria because polyp type was unknown (16.7%

(1/6)). The final case of disagreement arose because the tool does not currently allow entry of half-relationships (16.7% (1/6)).

Performance of the tool depends on the accuracy of the underlying algorithm in assessing that specific aspects of the patient's personal and/or family history meet criteria. To further validate the tool, we compared the tool's and research team's assessment of which specific aspects of the patient's history met criteria for a subset of cases (40.8% (62/152)). This involved comparing the history-based rule(s) in the tool's algorithm that were triggered for each case to the research team's assessment of which history-based rule(s) should have been triggered. This subset of cases had similar characteristics to the overall sample (Supplemental Table 1), with the exception that they all met criteria for genetic testing (as assessed by the GC). In all cases, the research team and the tool agreed on (100% (62/62)) which aspects of the patient's personal and family history met criteria for genetic testing. Across these 62 cases, specific aspects of the patient's history were recognized by 65 different rules in the tool's algorithm, and these rules were triggered a total of 269 times across the 62 patient cases, with complete agreement between the tool and research team each time they were triggered (100% (269/269)). Each rule was triggered by a mean of 3.8 cases (SD 3.5) and the mean number of rules triggered per case was 4.1 (SD 2.7). All algorithm rules that are used in clinical practice with the highest frequency were validated individually (100% (37/37)), as were most intermediate frequency rules (68.4% (26/38)) (Table 3). The majority of individual rules in the following cancer types were validated: breast, ovarian, pancreatic (71.7% (33/46)); colorectal, endometrial (93.3% (14/15)); prostate (69.6% (16/23)) (Table 3).

DISCUSSION

We observed a high level of agreement between the tool and GCs, which suggests that the tool is accurate in its assessments of whether patients meet criteria for genetic testing. The rate of agreement we observed was markedly higher than that seen by Cohn et al, similar to that seen by Baumgart et al and slightly lower than that reported by Bucheit et al^{28, 30}. It is also at the high end of the range of accuracy reported by USPTF in their review of several less automated hereditary cancer risk assessment tools⁴⁰. Furthermore, we found complete agreement between the tool and the study team on which specific aspects of a patient's personal and family history meet criteria. This is particularly critical when hereditary cancer risk assessment is done in primary care or other population-based settings since many unaffected patients in such settings qualify for genetic testing based on just one aspect of their family history³⁵. Taken together, these findings suggest the tool has an acceptable level of accuracy that is higher than or comparable to other risk assessment tools. It is also notable that the tool was validated using cases meeting criteria for a variety of hereditary cancer predispositions. Other digital risk assessment tools, and also validation of those tools, have primarily focused only on BRCA1/2 and Lynch syndrome^{27, 28, 30}. In contrast, the current validation covered risk for a wide range of cancers, cancer syndromes, and tumors, all of which the tool is programmed to detect (Table 1). Another strength of this study is the use of real patient cases, in contrast to prior work on validation of digital risk assessment tools which has relied, at least in part, on fictitious cases²⁸.

It is worth considering the minority of cases where the tool and GC disagreed. Of note, none of the disagreements were due to errors in the functioning of the tool. Most

disagreements occurred because of history questions that were intentionally left out of the tool (ex. MSI/IHC (3 cases), PREMM5 (1 case)) due to our clinical experience that patients do not have the necessary information to answer such questions. Asking more questions and questions patients can't answer can increase cognitive burden and decrease usability, both of which have been shown to decrease patient engagement with digital health tools^{41, 42}. RISE was intentionally designed to be brief to maximize completion rates; we've found that more than 95% of patients complete the tool, with most patients completing the tool in less than 3 minutes³⁵. Given that MSI/IHC contributed to disagreement in multiple cases, we could add a question on that to the tool and then study whether patients can answer it and whether completion rates decrease. An additional area for improvement of the tool is the addition of half-relationships, as this contributed to disagreement in one case.

The high level of agreement between the tool and GCs that we observed, combined with prior research on feasibility and acceptability of genomics digital tools,^{27, 33, 36–38, 43–45} supports them as promising solutions to increasing access to hereditary cancer risk assessment without burdening clinicians. In a recent systematic review, Lee et al found that 84% of 87 studies on digital tools in genomics reported a positive outcome and that digital tools increased provider efficiency and decreased the time providers need to spend with patients³⁶. Hereditary cancer risk assessment tools could also make periodic re-assessment more feasible, which is recommended by guidelines.⁶ While recent studies demonstrate that such tools effectively identify at-risk patients who were otherwise un-ascertained, they also find that additional implementation work is needed to increase the proportion of these at-risk patients who go on to have genetic testing.^{46, 47} This

demonstrates that innovation and practice improvement are needed at multiple steps in the care pathway to ensure access to the benefits of genomic medicine.

An important limitation of this work is that patient histories were not entered by patients themselves, but instead by the research team. While the validation covered a range of aspects of history and types of hereditary cancer risk, it was not exhaustive; we did not validate every rule in the algorithm or every way a given criteria could be met. Additionally, since the cases included in our study had already been assessed as needing genetic counseling, they are not representative of a lower-risk population. We did not have sufficient variance in disagreement in assessment or either race or ethnicity to be able to investigate disparities in the tool's performance. Multiple studies have found disparities in cancer genetics care based on race^{48, 49}, ethnicity, and socioeconomic status⁴. While digital tools have potential to reduce disparities, care in their design, implementation, and evaluation is needed to ensure they perform and benefit patients equitably. Finally, our sampling method did not allow for calculation of sensitivity and specificity.

CONCLUSION

We observed a high degree of agreement between the digital tool and cancer genetic counselors' assessments of whether patients meet criteria for germline genetic testing. Combined with prior findings on feasibility, acceptability, and efficiency of digital tools in genomics, our results suggest that RISE Risk Assessment Module: Hereditary Cancer could help increase access to hereditary cancer risk assessment and genetic testing without significantly burdening clinicians.

ACKNOWLEDGEMENTS

We thank Caitlin Campbell for assistance with writing and both Isabela Dall'Oglio Bucco and Cecilia Kessler for administrative assistance.

REFERENCES

1. Owens DK, Douglas K, Davidson KW, et al: Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. *JAMA* 322:652–665, 2019
2. Childers CP, Childers KK, Maggard-Gibbons M, et al: National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer. *J Clin Oncol* 35:3800–3806, 2017
3. Parente DJ: BRCA-Related Cancer Genetic Counseling is Indicated in Many Women Seeking Primary Care. *J Am Board Fam Med* 33:885–893, 2020
4. Linfield DT, Rothberg MB, Pfoh ER, et al: Primary care physician referral practices regarding BRCA1/2 genetic counseling in a major health system. *Breast Cancer Res Treat* 195:153–160, 2022
5. Haverfield EV, Esplin ED, Aguilar SJ, et al: Physician-directed genetic screening to evaluate personal risk for medically actionable disorders: a large multi-center cohort study. *BMC Med* 19:199, 2021
6. Daly MB, Pal T, Maxwell KN, et al: NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024. *J Natl Compr Canc Netw* 21:1000–1010, 2023
7. Domchek SM, Friebel TM, Singer CF, et al: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. *JAMA* 304:967–975, 2010

- 8.** Buchanan AH, Manickam K, Meyer MN, et al: Early cancer diagnoses through BRCA1/2 screening of unselected adult biobank participants. *Genet Med* 20:554–558, 2018
- 9.** ASCO Releases Rapid Guideline Recommendation Update for Certain Patients With Hereditary Breast Cancer [Internet]. ASCO , 2021[cited 2023 May 8] Available from: <https://old-prod.asco.org/about-asco/press-center/news-releases/asco-releases-rapid-guideline-recommendation-update-certain>
- 10.** Therkildsen C, Jensen LH, Rasmussen M, et al: An Update on Immune Checkpoint Therapy for the Treatment of Lynch Syndrome. *Clin Exp Gastroenterol* 14:181–197, 2021
- 11.** Hereditary cancer syndromes and risk assessment. *Obstet Gynecol* 134:1366–1367, 2019
- 12.** U.S. Preventive Services Task Force: Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. *Ann Intern Med* 143:355–361, 2005
- 13.** Hampel H, Bennett RL, Buchanan A, et al: A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. *Genet Med* 17:70–87, 2015
- 14.** Katz SJ, Ward KC, Hamilton AS, et al: Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer. *J Clin Oncol* 36:1218–1224, 2018
- 15.** Kurian AW, Ward KC, Abrahamse P, et al: Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019. *J Clin Oncol* 39:1631–1640, 2021
- 16.** Kurian AW, Abrahamse P, Furgal A, et al: Germline Genetic Testing After Cancer Diagnosis. *JAMA* 330:43–51, 2023
- 17.** Chun DS, Berse B, Venne VL, et al: BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines. *Fam Cancer* 16:41–49, 2017

- 18.** Harding B, Webber C, Ruhland L, et al: Primary care providers' lived experiences of genetics in practice. *J Community Genet* 10:85–93, 2019
- 19.** Evenson SA, Hoyme HE, Haugen-Rogers JE, et al: Patient and Physician Perceptions of Genetic Testing in Primary Care. *S D Med* 69:487–493, 2016
- 20.** Bombard Y, Ginsburg GS, Sturm AC, et al: Digital health-enabled genomics: Opportunities and challenges. *Am J Hum Genet* 109:1190–1198, 2022
- 21.** Dusic EJ, Theorin T, Wang C, et al: Barriers, interventions, and recommendations: Improving the genetic testing landscape. *Front Digit Health* 4:961128, 2022
- 22.** Son Y, Lim MC, Seo SS, et al: Completeness of pedigree and family cancer history for ovarian cancer patients. *J Gynecol Oncol* 25:342–348, 2014
- 23.** Arun BK, Peterson SK, Sweeney LE, et al: Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center. *Cancer* 128:94–102, 2021
- 24.** Shore ND, Lenz L, Flake DD, et al: Hereditary cancer risk assessment in the community urology practice setting. *J Clin Orthod* 40:278–278, 2022
- 25.** Hessock M, Brewer T, Hutson S, et al: Use of a Standardized Tool to Identify Women at Risk for Hereditary Breast and Ovarian. *Nurs Womens Health* 25:187–197, 2021
- 26.** Rao SK, Thomas KA, Singh R, et al: Increased ease of access to genetic counseling for low-income women with breast cancer using a point of care screening tool. *J Community Genet* 12:129–136, 2021
- 27.** Nazareth S, Hayward L, Simmons E, et al: Hereditary Cancer Risk Using a Genetic Chatbot Before Routine Care Visits. *Obstet Gynecol* 138:860–870, 2021
- 28.** Bucheit L, Johansen Taber K, Ready K: Validation of a digital identification tool for individuals at

risk for hereditary cancer syndromes. *Hered Cancer Clin Pract* 17:2, 2019

29. Wu RR, Myers RA, Neuner J, et al: Implementation-effectiveness trial of systematic family health history based risk assessment and impact on clinical disease prevention and surveillance activities. *BMC Health Serv Res* 22:1486, 2022

30. Cohn WF, Ropka ME, Pelletier SL, et al: Health Heritage© a web-based tool for the collection and assessment of family health history: initial user experience and analytic validity. *Public Health Genomics* 13:477–491, 2010

31. Shi J, Morgan KL, Bradshaw RL, et al: Identifying Patients Who Meet Criteria for Genetic Testing of Hereditary Cancers Based on Structured and Unstructured Family Health History Data in the Electronic Health Record: Natural Language Processing Approach. *JMIR Med Inform* 10:e37842, 2022

32. Henderson V, Ganschow P, Wang C, et al: Population screening to identify women at risk for hereditary breast cancer syndromes: The path forward or the road not taken? *Cancer* 128:30–33, 2022

33. Nazareth S, Nussbaum RL, Siglen E, et al: Chatbots & artificial intelligence to scale genetic information delivery. *J Genet Couns* 30:7–10, 2021

34. Smith C, Caleshu C, Bonadies D, et al: Use of digital health tools with point-of-care testing improves access to germline genetic testing within a gastrointestinal cancer clinic. *CGA-IGC 2023 Abstracts* [Internet]. *Fam Cancer*, 2024 Available from: <http://dx.doi.org/10.1007/s10689-023-00352-1>

35. Petersen J, Hila A, Johnson K, et al: A digital hereditary cancer risk assessment tool efficiently identifies patients in need of genetic evaluation; Abstract. Presented at the 41st NSGC Annual Conference, November 16-20 2022, Nashville, TN

36. Lee W, Shickh S, Assamad D, et al: Patient-facing digital tools for delivering genetic services: a

systematic review. *J Med Genet* 60:1–10, 2023

37. Grimmett C, Brooks C, Recio-Saucedo A, et al: Development of Breast Cancer Choices: a decision support tool for young women with breast cancer deciding whether to have genetic testing for BRCA1/2 mutations. *Support Care Cancer* 27:297–309, 2019

38. Bombard Y, Clausen M, Mighton C, et al: The Genomics ADvISER: development and usability testing of a decision aid for the selection of incidental sequencing results. *Eur J Hum Genet* 26:984–995, 2018

39. Kastrinos F, Uno H, Ukaegbu C, et al: Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome. *J Clin Oncol* 35:2165–2172, 2017

40. Nelson HD, Pappas M, Cantor A, et al: Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force. Rockville (MD), Agency for Healthcare Research and Quality (US), 2019

41. Wei Y, Zheng P, Deng H, et al: Design Features for Improving Mobile Health Intervention User Engagement: Systematic Review and Thematic Analysis. *J Med Internet Res* 22:e21687, 2020

42. Szinay D, Jones A, Chadborn T, et al: Influences on the Uptake of and Engagement With Health and Well-Being Smartphone Apps: Systematic Review. *J Med Internet Res* 22:e17572, 2020

43. Gordon EJ, Gacki-Smith J, Gooden MJ, et al: Development of a culturally targeted chatbot to inform living kidney donor candidates of African ancestry about APOL1 genetic testing: a mixed methods study [Internet]. *J Community Genet* , 2024 Available from:

<http://dx.doi.org/10.1007/s12687-024-00698-8>

44. Schmidlen T, Jones CL, Campbell-Salome G, et al: Use of a chatbot to increase uptake of cascade genetic testing. *J Genet Couns* 31:1219–1230, 2022

45. Siglen E, Vetti HH, Augestad M, et al: Evaluation of the Rosa Chatbot Providing Genetic

Information to Patients at Risk of Hereditary Breast and Ovarian Cancer: Qualitative Interview Study. *J Med Internet Res* 25:e46571, 2023

46. Wang C, Lu H, Bowen DJ, et al: Implementing digital systems to facilitate genetic testing for hereditary cancer syndromes: An observational study of 4 clinical workflows. *Genet Med* 25:100802, 2023

47. Loving VA, Luiten RC, Siettmann JM, et al: A Breast Radiology Department-operated, Proactive Same-day Program Identifies Pathogenic Breast Cancer Mutations in Unaffected Women. *Acad Radiol* 29 Suppl 1:S239–S245, 2022

48. Hesse-Biber S, Seven M, Shea H, et al: Racial and Ethnic Disparities in Genomic Healthcare Utilization, Patient Activation, and Intrafamilial Communication of Risk among Females Tested for BRCA Variants: A Mixed Methods Study [Internet]. *Genes* 14, 2023 Available from: <http://dx.doi.org/10.3390/genes14071450>

49. Frey MK, Finch A, Kulkarni A, et al: Genetic Testing for All: Overcoming Disparities in Ovarian Cancer Genetic Testing. *Am Soc Clin Oncol Educ Book* 42:1–12, 2022

SOURCES OF FUNDING

None

TABLES

Table 1: RISE assesses hereditary risk for a variety of cancers, hereditary cancer syndromes, and tumors

Cancers	Hereditary cancer syndromes	Tumors
Breast	Attenuated familial adenomatous polyposis (AFAP)	Paranglioma
Colorectal	Classical familial adenomatous polyposis (FAP)	Pheochromocytoma
Gastric	Cowden	
Kidney	Diffuse gastric cancer and lobular breast cancer	
Medullary thyroid	Hereditary breast and ovarian cancer (HBOC)	
Ovarian	Li-Fraumeni	
Pancreatic	Lynch	
Prostate	MUTYH-associated polyposis (MAP)	
Uterine		

Table 2: Patient Characteristics

	All Cases	Met Criteria*	
		Yes	No
Age[^]	52.3 (SD 15.9)	55.3 (SD 15.4)	45.8 (SD 15.3)
Sex			
Female	121/152 (79.6%)	78/99 (78.8%)	40/47 (85.1%)
Male	31/152 (20.4%)	21/99 (21.2%)	7/47 (14.9%)
Race			
American Indian or Alaska Native	1/138 (0.7%)	1/98(1.0%)	-
Asian	3/138 (2.2%)	1/98(1.0%)	2/40 (5.0%)
Black or African American	11/138 (8.0%)	8/98(8.2%)	3/40 (7.5%)
Other Race	7/138 (5.1%)	5/98(5.1%)	2/40 (5.0%)
White	116/138 (84.1%)	83/98(84.7%)	33/40 (82.5%)
Ethnicity			
Hispanic or Latino	12/134 (9.0%)		
Personal History of Cancer			
Any diagnosis of cancer	85/152 (55.9%)	69/99 (69.7%)	16/47 (34.0%)
Multiple primary diagnoses	27/152 (17.8%)	24/99 (24.2%)	3/47 (6.4%)

<i>Cancer type^Δ</i>			
Breast	30/152 (19.7%)	21/99 (21.2%)	9/47 (19.1%)
Colorectal	15/152 (9.9%)	14/99 (14.1%)	2/47 (4.3%)
Uterine	14/152 (9.2%)	14/99 (14.1%)	-
Prostate	10/152 (6.6%)	10/99 (10.1%)	-
Ovarian	7/152 (4.6%)	7/99 (7.1%)	-
Pancreatic	7/152 (4.6%)	7/99 (7.1%)	-
Kidney	2/152 (1.3%)	1/99 (1.0%)	1/47 (2.1%)

Family History of Cancer

At least one relative with cancer	140/152 (92.1%)	99/99 (100%)	41/47 (87.2%)
-----------------------------------	-----------------	--------------	---------------

<i>Cancer type^Δ</i>			
Breast	86/152 (56.6%)	66/99 (66.7%)	20/47 (42.6%)
Prostate	43/152 (28.3%)	36/99 (36.4%)	7/47 (14.9%)
Colorectal	42/152 (27.6%)	31/99 (31.3%)	11/47 (23.4%)
Pancreatic	33/152 (21.7%)	22/99 (22.2%)	11/47 (23.4%)
Ovarian	23/152 (15.1%)	21/99 (21.2%)	2/47 (4.3%)
Uterine	14/152 (9.2%)	12/99 (12.1%)	2/47 (4.3%)
Kidney	13/152 (8.6%)	10/99 (10.1%)	3/47 (6.4%)
Stomach or Gastric	10/152 (6.6%)	8/99 (8.1%)	2/47 (4.3%)
Thyroid	8/152 (5.3%)	6/99 (6.1%)	2/47 (4.3%)

* Met criteria based on genetic counselor's assessment

^Δ Mean (standard deviation)

^Δ Total number of individual cancer diagnoses of that cancer type

Table 2: Rules Validated

Cancer Group	Frequency of Rule			Total
	High	Moderate	Low	
Breast, Ovarian, Pancreatic	26/26 (100%)	7/10 (70%) 10/15	0/9 (0%)	33/46 (72%)
Prostate	5/5 (100%)	(67%)	1/3 (33%)	16/23 (70%)
Colorectal/Endometrial	5/5 (100%)	9/10 (90%)	-	14/15 (93%)
Thyroid	-	-	0/1 (0%)	0/1 (0%)
Kidney	-	0/2 (0%)	1/1 (100%)	1/3 (33%)
Gastric	-	0/1 (0%)	0/8 (0%)	0/9 (0%)
Neuroendocrine/Adrenal	-	-	0/1 (0%)	0/1 (0%)
Known Familial Mutation	1/1 (100%)	-	-	1/2 (50%)
Total	37/38 (97.4%)	26/38 (68%)	2/23 (8.7%)	

FIGURES




Figure 1. Screenshots of various steps in the digital tool including the welcome page, a history question, a family history question, and the assessment. Images courtesy of Genome Medical. Used with permission.




Figure 2. High level of agreement between tool and genetic counselor (A) Stacked bar chart showing the percentage of cases with agreement in assessments made by the tool and the GC (96% (146/152)) (B) Reasons for disagreement in the 3.9% (6/152) of cases where the tool's and GC's assessments differed. The tool does not ask about clinical details patients typically cannot report such as

MSI/IHC and risk of having a germline pathogenic variant based on the PREDiction Model for gene Mutations (PREMM5), nor does it account for half relationships. In one case the GC's application of their clinical judgment in interpreting a patient's history of polyps contributed to disagreement. a. PREMM = PREDiction Model for gene Mutations. b. MSI/IHC = Microsatellite Instability/Immunohistochemistry.

SUPPLEMENTAL MATERIAL

Supplemental Table 1: Characteristics of Cases Used for Rule Validation

	All cases
Age[^]	54.3 (SD 13.3)
Sex	
Female	50/62 (80.6%)
Male	12/62 (19.4%)
Personal History of Cancer	
Any diagnosis of cancer	34/62 (54.8%)
Multiple primary diagnoses	10/62 (16.1%)
<i>Cancer Type^{\$}</i>	
Breast	19/62 (30.1%)
Prostate	10/62 (16.1%)
Colorectal	5/62 (8.1%)
Uterine	4/62 (6.5%)
Kidney	2/62 (3.2%)
Ovarian	2/62 (3.2%)
Pancreatic	2/62 (3.2%)
Family History of Cancer	
At least one relative with cancer	58/62 (93.5%)
<i>Cancer type^{\$}</i>	
Breast	43/62 (69.4%)
Prostate	27/62 (43.6%)
Colorectal	20/62 (32.3%)
Ovarian	12/62 (19.4%)
Pancreatic	15/62 (24.2%)
Uterine	9/62 (14.5%)
Kidney	9/62 (14.5%)
Stomach or Gastric	6/62 (9.7%)
Thyroid	2/62 (3.2%)

[^] Mean (standard deviation)

\$ Total number of individual cancer diagnoses of that cancer type